Humana's Fourth Quarter Earnings: A Mixed Prescription for Investors

Published: February 2, 2022

Humana Inc. Reports 4Q21 Results

Humana Inc. (NYSE: HUM) recently released its fourth quarter financial results, and let?s just say the numbers are more of a prescription than a panacea. The company reported a loss per common share of $0.11 on a GAAP basis, which is certainly not what one would expect when examining EPS expectations. In contrast, the Adjusted EPS came in at a more palatable $1.24, suggesting that the company is still managing to find some green shoots among the thorns.

Analyzing the Earnings Surprise

While the reported loss might raise eyebrows, it was largely in line with the EPS consensus. Investors often hold their breath during earnings season, hoping for an earnings surprise that could send shares soaring. Here, however, the results are akin to a lukewarm cup of coffee?neither invigorating nor disappointing enough to warrant a second look.

Full Year Guidance: A Cautious Outlook

Looking ahead, Humana has set its sights on a full year 2022 EPS guidance of at least $23.08 on a GAAP basis and at least $24.00 on an Adjusted basis. This guidance factors in a COVID-19-related headwind of $1.00, which the company openly acknowledges. The revenue forecast appears cautious, but in these uncertain times, perhaps a conservative estimate is the best approach. Investors will be watching closely to see if Humana can navigate through this headwind successfully.

Cost Savings and Growth Initiatives

In a move that suggests a proactive approach, Humana has committed to driving an impressive $1 billion of additional value through various cost-saving measures and productivity initiatives. This commitment aims to create capacity for growth, particularly in the Medicare Advantage space. If executed effectively, these initiatives could position Humana favorably against its sector peers, especially as the demand for healthcare services continues to rise.

Reactions from the Market

Market reactions to earnings reports can be as unpredictable as the weather in spring. While some analysts may perceive the loss as a signal for caution, others might see the potential for growth through the strategic plans laid out by management. Humana?s focus on Medicare Advantage and healthcare service expansion could make it a compelling story moving forward, particularly as the aging population continues to seek reliable healthcare solutions.

Conclusion: A Watchful Eye

As Humana navigates the choppy waters of 2022, investors would do well to keep a watchful eye on the company?s progress against its earnings forecast and growth commitments. While the recent results may not have set the world ablaze, there is a sense that Humana is laying the groundwork for a robust recovery. For now, it?s a waiting game, but with a few strategic plays, Humana could very well turn the tide.